A PHASE 3, GLOBAL, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, EFFICACY STUDY OF IMAB362 PLUS MFOLFOX6 COMPARED WITH PLACEBO PLUS MFOLFOX6 AS FIRST-LINE TREATMENT OF SUBJECTS WITH CLAUDIN (CLDN)18.2-POSITIVE, HER2-NEGATIVE, LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) ADENOCARCINOMA
- Registry ID
- 8951-CL-0301
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ASTELLAS PHARMA GLOBAL DEVELOPMENT INC
- Start date
- 2020-01-13
- Last update
- 2018-06-22
Conditions
- GASTROESOPHAGEAL JUNCTION CANCER
Related clinical trials
- ROSETTA GASTRIC-204: A BLINDED, RANDOMIZED, PHASE 2/3 STUDY OF PUMITAMIG IN COMBINATION WITH CHEMOTHERAPY VERSUS NIVOLUMAB IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED ADVANCED OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA
- A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF TRASTUZUMAB
DERUXTECAN (ENHERTU®) PLUS CHEMOTHERAPY PLUS OR MINUS PEMBROLIZUMAB VERSUS
CHEMOTHERAPY PLUS TRASTUZUMAB PLUS OR MINUS PEMBROLIZUMAB AS FIRST-LINE
TREATMENT IN PARTICIPANTS WITH UNRESECTABLE, LOCALLY ADVANCED OR METASTATIC
HER2POSITIVE GASTRIC OR GASTROESOPHAGEAL JUNCTION (GEJ) CANCER (DESTINYGASTRIC05)
- A PHASE 2 RANDOMIZED STUDY TO EVALUATE THE SAFETY, EFFICACY, AND OPTIMAL DOSE OF ABBV-400 IN COMBINATION WITH FLUOROURACIL, LEUCOVORIN, AND BUDIGALIMAB AS FIRST-LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA (ANDROMETA-GEA-977)
- A PHASE 1B/2 OPEN-LABEL STUDY OF DISITAMAB VEDOTIN MONOTHERAPY OR IN COMBINATION WITH OTHER ANTICANCER THERAPIES IN SOLID TUMORS
- A RANDOMIZED, OPEN-LABEL, MULTICENTER PHASE 3 TRIAL OF DOMVANALIMAB, ZIMBERELIMAB, AND CHEMOTHERAPY VERSUS NIVOLUMAB AND CHEMOTHERAPY IN PARTICIPANTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED UNRESECTABLE OR METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, AND ESOPHAGEAL ADENOCARCINOMA
- A PHASE 1B/3 STUDY OF BEMARITUZUMAB PLUS CHEMOTHERAPY AND NIVOLUMAB VERSUS CHEMOTHERAPY AND NIVOLUMAB ALONE IN SUBJECTS WITH PREVIOUSLY UNTREATED ADVANCED GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER WITH FGFR2B OVEREXPRESSION (FORTITUDE 102)
View on source registry